Price
$268.98
Decreased by -0.02%
Dollar Volume (20D)
602.04 M
ADR%
1.71
Earnings Report Date (estimate)
Nov 1, 23 (4.68)
Market Cap.
143.88 B
Shares Float
533.76 M
Shares Outstanding
534.90 M
Beta
0.61
Price / Earnings
18.13
BPR
1.80
20D Range
248.38 273.61
50D Range
228.21 273.61
200D Range
211.71 285.17
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Aug 3, 23 5.00
Increased by +7.53%
4.44
Increased by +12.61%
Apr 27, 23 3.98
Decreased by -6.35%
3.85
Increased by +3.38%
Jan 31, 23 4.09
Decreased by -6.19%
4.09
Nov 3, 22 4.70
Increased by +0.64%
4.44
Increased by +5.86%
Aug 4, 22 4.65
Increased by +6.16%
4.40
Increased by +5.68%
Apr 27, 22 4.25
Increased by +14.86%
4.09
Increased by +3.91%
Feb 7, 22 4.36
Increased by +14.44%
4.08
Increased by +6.86%
Nov 2, 21 4.67
Increased by +6.86%
4.27
Increased by +9.37%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Jun 30, 23 6.99 B
Increased by +5.94%
1.38 B
Increased by +4.71%
Increased by +19.74%
Decreased by -1.17%
Mar 31, 23 6.11 B
Decreased by -2.13%
2.84 B
Increased by +92.48%
Increased by +46.54%
Increased by +96.67%
Dec 31, 22 6.84 B
Decreased by -0.10%
1.62 B
Decreased by -14.90%
Increased by +23.63%
Decreased by -14.82%
Sep 30, 22 6.65 B
Decreased by -0.81%
2.14 B
Increased by +13.75%
Increased by +32.22%
Increased by +14.67%
Jun 30, 22 6.59 B
Increased by +1.04%
1.32 B
Increased by +183.84%
Increased by +19.97%
Increased by +180.91%
Mar 31, 22 6.24 B
Increased by +5.71%
1.48 B
Decreased by -10.33%
Increased by +23.66%
Decreased by -15.17%
Dec 31, 21 6.85 B
Increased by +3.20%
1.90 B
Increased by +17.59%
Increased by +27.74%
Increased by +13.94%
Sep 30, 21 6.71 B
Increased by +4.41%
1.88 B
Decreased by -6.78%
Increased by +28.09%
Decreased by -10.71%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.